Alliance Pharma PLC AGM Statement (0566Z)
May 19 2021 - 1:00AM
UK Regulatory
TIDMAPH
RNS Number : 0566Z
Alliance Pharma PLC
19 May 2021
For immediate release 19 May 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Group")
AGM Statement
Alliance Pharma plc (AIM: APH), the international healthcare
group, will hold its Annual General Meeting ("AGM") at 10.00am this
morning. At the meeting, the Group's Chairman, David Cook, will
make the following statement:
"Firstly, on behalf of the Alliance Board, I would like to take
this opportunity to thank Alliance's employees around the world for
their continued commitment and support through what for many, has
been an extended period of remote working.
"As reported in March 2021, the year started well for the Group
and we continue to see some strong performances from our key
brands.
"Integration of the Biogix business and the Amberen brand into
our US-based operations is progressing very well, with integration
almost complete. Current trading and expectations for Amberen
remain in line with our pre-acquisition forecasts.
"We remain confident in our ability to weather any ongoing
disruption to our business in those areas of the world which
continue to be challenged by the global pandemic, and to deliver
full year results in line with market expectations.
"Further commentary on our first half trading performance and
full year outlook will be provided in mid July 2021 in our half
year trading update."
AGM 2021: Access details for shareholders
Alliance's AGM is being held as a hybrid meeting at Group's head
office, Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB
, alongside a live and interactive broadcast to shareholders.
As detailed in the Notice of AGM, a copy of which can be viewed
at
https://www.alliancepharmaceuticals.com/media/j2phk41u/alliance-pharma-agm-notice-final.pdf
, we are strongly urging shareholders not to attend the AGM in
person this year but instead take part in the AGM remotely, using
the access details below:
Meeting website: https://web.lumiagm.com
Meeting ID: 145-852-162
Shareholders will also require their unique 11-digit Investor
Code (IVC) and PIN to access the meeting. Full details on how to
attend the 2021 AGM and vote can be found in the AGM Notice.
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
alliancepharma@buchanan.uk.com
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Oliver Steele
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group, headquartered in the UK with subsidiaries in Europe, the Far
East and the US and wide international reach through an extensive
network of distributors, generating sales in more than 100
countries.
We hold the marketing rights to around 80 Consumer Healthcare
brands and Prescription Medicines, which are managed on a portfolio
basis according to their growth potential. Promotional investment
is focused primarily on our Consumer healthcare brands, many of
which have significant international or multi-territory reach. Our
Prescription Medicines are generally sold in a more limited number
of local markets, and most require little or no promotional
investment.
Our strategy allows us to deliver good organic growth and to
enhance our growth rate through carefully selected
acquisitions.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMDKFBKOBKDDPD
(END) Dow Jones Newswires
May 19, 2021 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024